Ultragenyx Pharmaceutical(MX:RARE)
MX$256.000.00 (0.00%)
MX:RARE
Ultragenyx Pharmaceutical ownership
MX$256.00
At close:0.00 (0.00%)
Ultragenyx Pharmaceutical (RARE) Ownership - Who Owns Ultragenyx Pharmaceutical?
1 Followers
Ultragenyx Pharmaceutical (RARE) Ownership Overview
- 3.81% Insiders
- 20.39% Mutual Funds
- 5.49% Other Institutional Investors
- 20.67% ETFs
- 49.64% Public Companies and Individual Investors
The ownership structure of Ultragenyx Pharmaceutical (MX:RARE) stock is a mix of institutional, retail, and individual investors. Approximately 46.55% of the company’s stock is owned by Institutional Investors, 3.81% is owned by Insiders, and 49.64% is owned by Public Companies and Individual Investors.
The ownership structure of Ultragenyx Pharmaceutical (MX:RARE) stock is a mix of institutional, retail, and individual investors. Approximately 46.55% of the company’s stock is owned by Institutional Investors, 3.81% is owned by Insiders, and 49.64% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Oct 18, 2026 | Howard Horn | $107,898 | |
| Sep 14, 2026 | Theodore Alan Huizenga | $17,410 | |
| Sep 07, 2026 | Theodore Alan Huizenga | $2,252 | |
| Aug 03, 2026 | Howard Horn | $117,024 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 10,654,276 | Institution | 10.45% | 146,613,492 |
| Vanguard | 8,443,338 | Institution | 8.28% | 116,188,774 |
| Vanguard Index Funds | 7,497,774 | Institution | 7.36% | 103,176,868 |
| Spdr | 5,745,686 | Institution | 5.64% | 79,066,385 |
| Ishares | 4,741,605 | Institution | 4.65% | 65,249,226 |
| Frank Sands | 3,158,368 | Institution | 3.10% | 43,462,302 |
| Emil Kakkis | 2,894,724 | Insider | 2.84% | 39,834,297 |
| Felix Baker | 2,772,692 | Institution | 2.72% | 38,155,015 |
| Vanguard Horizon Funds | 1,551,402 | Institution | 1.52% | 21,348,843 |
| Fidelity Salem Street Trust | 1,190,194 | Institution | 1.17% | 16,378,260 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 7,497,774 | Institution | 7.36% | 103,176,868 |
| Vanguard Horizon Funds | 1,551,402 | Institution | 1.52% | 21,348,843 |
| Fidelity Salem Street Trust | 1,190,194 | Institution | 1.17% | 16,378,260 |
| Fidelity Concord Street Trust | 999,015 | Institution | 0.98% | 13,747,445 |
| Aqr Funds | 901,932 | Institution | 0.88% | 12,411,486 |
| Vanguard Explorer Fund | 821,986 | Institution | 0.81% | 11,311,349 |
| Vanguard Scottsdale Funds | 659,758 | Institution | 0.65% | 9,078,930 |
| Tiaa-cref Funds | 638,534 | Institution | 0.63% | 8,786,866 |
| Touchstone Funds Group Trust | 611,950 | Institution | 0.60% | 8,421,044 |
| Blackrock Funds | 551,135 | Institution | 0.54% | 7,584,169 |
FAQ
Who Owns Ultragenyx Pharmaceutical (MX:RARE)?
According to the latest TipRanks data, approximately 46.55% of the company's stock is held by institutional investors, 3.81% is held by insiders, and 49.64% is held by public companies and individual investors.
What percentage of Ultragenyx Pharmaceutical (MX:RARE) stock is held by institutional investors?
According to the latest TipRanks data, approximately 46.55% of Ultragenyx Pharmaceutical (MX:RARE) stock is held by institutional investors: 20.39% by mutual funds, 20.67% by ETFs and 5.49% by other institutional investors.
What percentage of Ultragenyx Pharmaceutical (MX:RARE) stock is held by retail investors?
According to the latest TipRanks data, approximately 49.64% of Ultragenyx Pharmaceutical (MX:RARE) stock is held by public companies and individual investors.
Who owns the most shares of Ultragenyx Pharmaceutical (MX:RARE)?
BlackRock, Inc. owns the most shares of Ultragenyx Pharmaceutical (MX:RARE).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
